A targeted prostate cancer screening programme could be possible in five years - what will it look like? 28 Jan 2022 The UK began screening for breast cancer nearly 35 years ago but we’re yet to have a screening programme for prostate cancer. Julia Bakker spoke to the UK’s leading expert in prostate cancer genetics, the ICR’s Professor Ros Eeles, about the progress we’re making and when we can expect prostate cancer screening to be a reality. Find out more Show/Hide
ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 04 Jun 2021 The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. We spoke to Chair of the OlympiA steering committee Professor Andrew Tutt about the landmark ICR research that underpins this major breakthrough. Find out more Show/Hide
“Being told I had the BRCA2 mutation effectively saved my life” – Tony’s story 23 Dec 2020 After both he and his sister were diagnosed with breast cancer, Tony Herbert decided to undergo genetic testing to see if he had a BRCA mutation. Here he talks about how the result may have saved his life. Find out more Show/Hide
“Here you really can make a difference” – Professor Chris Lord reflects on the biggest developments in his career so far 18 Oct 2018
ASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation 07 Jun 2017